Page last updated: 2024-09-05

sb 203580 and milrinone

sb 203580 has been researched along with milrinone in 2 studies

Compound Research Comparison

Studies
(sb 203580)
Trials
(sb 203580)
Recent Studies (post-2010)
(sb 203580)
Studies
(milrinone)
Trials
(milrinone)
Recent Studies (post-2010) (milrinone)
3,48941,1371,605235452

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)milrinone (IC50)
Phosphodiesterase Bos taurus (cattle)1
cGMP-dependent 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.3
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8AHomo sapiens (human)0.3
cGMP-specific 3',5'-cyclic phosphodiesteraseHomo sapiens (human)0.52
Prostaglandin G/H synthase 1Homo sapiens (human)4.7
cAMP-specific 3',5'-cyclic phosphodiesterase 4AHomo sapiens (human)6
cAMP-specific 3',5'-cyclic phosphodiesterase 4BHomo sapiens (human)6
cAMP-specific 3',5'-cyclic phosphodiesterase 4CHomo sapiens (human)6
cAMP-specific 3',5'-cyclic phosphodiesterase 4DHomo sapiens (human)3.15
cGMP-inhibited 3',5'-cyclic phosphodiesterase BHomo sapiens (human)1.8674
cGMP-inhibited 3',5'-cyclic phosphodiesterase AHomo sapiens (human)1.8177
cGMP-specific 3',5'-cyclic phosphodiesteraseBos taurus (cattle)5
Phosphodiesterase Sus scrofa (pig)0.843

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H1
Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J1

Other Studies

2 other study(ies) available for sb 203580 and milrinone

ArticleYear
Identifying off-target effects and hidden phenotypes of drugs in human cells.
    Nature chemical biology, 2006, Volume: 2, Issue:6

    Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship

2006
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.
    Circulation, 2001, Aug-07, Volume: 104, Issue:6

    Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Enzyme Inhibitors; Flavonoids; Hemodynamics; Imidazoles; Indoles; Isoquinolines; Maleimides; Milrinone; Mitogen-Activated Protein Kinases; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridines; Pyridones; Sulfonamides; Ventricular Fibrillation

2001